(TEM) Tempus AI Common Stock - Ratings and Ratios

Tempus AI, Inc. operates at the intersection of technology and healthcare, specializing in advanced diagnostic solutions and data-driven insights. The company leverages next-generation sequencing, PCR profiling, and molecular genotyping to deliver comprehensive anatomic and molecular pathology testing. Its services are utilized by healthcare providers, pharmaceutical firms, biotech companies, and researchers. Tempus AIs product portfolio includes Insights, a de-identified clinical and molecular data library, complemented by analytical tools for drug discovery and development. The company also offers Trials, a clinical trial matching platform designed to streamline patient recruitment for pharmaceutical companies. Additional offerings include Next, a suite of oncology-focused algorithmic tests; Hub, a platform for managing diagnostic workflows; and Lens, a research platform enabling access to Tempus data for scientific analysis. The company, rebranded from Tempus Labs, Inc. in January 2023, has been a key player in precision medicine since its founding in 2015. Headquartered in Chicago, Illinois, Tempus AI continues to expand its footprint in the life sciences and healthcare technology sectors.

Over the next three months, Tempus AI, Inc. (NASDAQ: TEM) is expected to exhibit volatility within a defined range. Based on the provided data, the stock is currently trading at $53.50, above its 20-day SMA of $44.73 and 50-day SMA of $53.01, but below its 200-day SMA of $49.87. This suggests short-term upward momentum but potential longer-term consolidation. The Average True Range (ATR) of 4.98 indicates expected price fluctuations of approximately $4.98 over the next month. Given the stocks current trajectory, it may test resistance near $58.50 or experience a pullback toward $48.50. Fundamental analysis highlights a market cap of $6,999.18M, a price-to-book ratio of 124.23, and a price-to-sales ratio of 10.09, reflecting high valuation multiples. These metrics suggest investor optimism about the companys growth prospects, though they also signal elevated risk. The lack of P/E ratios indicates the company is likely in a pre-profitability growth phase. Overall, the stock is expected to remain sensitive to broader market conditions and sector-specific news.